聚腺苷二磷酸核糖聚合酶 1 抑制剂引发非小细胞肺癌的免疫应答。

PARP1 inhibition elicits immune responses against non-small cell lung cancer.

机构信息

Equipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.

Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.

出版信息

Oncoimmunology. 2022 Aug 11;11(1):2111915. doi: 10.1080/2162402X.2022.2111915. eCollection 2022.

DOI:10.1080/2162402X.2022.2111915

PMID:35979387

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9377245/

Abstract

High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.

摘要

高水平的细胞内多聚（ADP-核糖）（PAR）源于 PAR 聚合酶-1（PARP1）的活性升高，与非小细胞肺癌中细胞毒性 T 淋巴细胞浸润不良和患者预后不良相关。目前的临床前实验表明，癌细胞中 PARP1 的抑制作用介导了强烈的免疫刺激作用。